Successful Treatment of Pemphigus Vulgaris With Ofatumumab
Overview
Affiliations
Rituximab is a chimeric anti-CD20 monoclonal antibody that is very effective in treating patients with pemphigus vulgaris. Though infrequent, the development of human anti-chimeric antibodies in patients receiving rituximab results in loss of efficacy. Ofatumumab is a second-generation fully-human anti-CD20 monoclonal antibody currently used to treat chronic lymphocytic leukemia. We report a case of a patient with pemphigus vulgaris successfully treated with ofatumumab after developing human anti-chimeric antibodies to rituximab. J Drugs Dermatol. 2018;17(12):1338-1339.
Consensus Based Indian Guidelines for the Management of Pemphigus Vulgaris and Pemphigus Foliaceous.
De D, Mehta H, Shah S, Ajithkumar K, Barua S, Chandrashekar L Indian Dermatol Online J. 2025; 16(1):3-24.
PMID: 39850690 PMC: 11753534. DOI: 10.4103/idoj.idoj_1059_24.
Updates on the Management of Autoimmune Bullous Diseases.
Choudhary R, Gupta V, Khandpur S Indian Dermatol Online J. 2024; 15(5):758-769.
PMID: 39359305 PMC: 11444445. DOI: 10.4103/idoj.idoj_740_23.
Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
Mantero V, Cordano C, Balgera R, Basilico P, Novi G, Salmaggi A J Neurol. 2023; 271(2):727-728.
PMID: 37907726 DOI: 10.1007/s00415-023-12082-6.
[Pemphigus: current and future treatment strategies].
Kussini J, Kaisers T, Sequeira Santos A, Eming R, Didona D Dermatologie (Heidelb). 2023; 74(12):915-926.
PMID: 37902884 DOI: 10.1007/s00105-023-05246-y.
Targeting therapy in pemphigus: Where are we now and where are we going?.
Abulikemu K, Hu F, Liang J, Kang X Heliyon. 2023; 9(6):e16679.
PMID: 37292301 PMC: 10245244. DOI: 10.1016/j.heliyon.2023.e16679.